Abstract
In order to evaluate the in vitro dissolution and in vivo bioavailability relationship for furosemide, a bioequivalence study was carried out. Furosemide (40 mg) was administered orally to 12 normal volunteers in a 6 × 6 crossover design using six products (five tablets and one solution) obtained from three pharmaceutical companies. Plasma and urine concentrations of furosemide were quantitated by high-performance liquid chromatography (HPLC). Plasma furosemide profiles were analyzed by non-compartmental methods. Compared to the oral solution, all of the formulations exhibited lower peak furosemide concentrations, longer mean residence times, and, in some cases, diminished bioavailability (range, 66–96%). Similar results were obtained when the reference product (a rapidly dissolving tablet) was used as the standard. All of the products failed the 75/75 rule when compared to either reference standard, apparently because of large intersubject variability. The total amount of furosemide excreted in urine could be associated with the percentage drug dissolved (in vitro) at 30 min. The pH 5.6 dissolution medium (compared to pH 4.6) appears to be an appropriate test medium for assuring batch uniformity and bioequivalence of furosemide products.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
G. Levy. Arch. Int. Pharmacodyn. 152:59–68 (1964).
G. Levy and L. E. Hollister. J. Pharm. Sci. 53:1446–1452 (1964).
C. Graffner, M. Nicklasson, and J.-K. Lindgren. J. Pharmacokin. Biopharm. 12:367–380 (1984).
V. P. Shah, V. K. Prasad, T. Alston, B. E. Cabana, R. P. Gural, and M. C. Meyer. J. Pharm. Sci. 72:306–308 (1983).
P. G. Welling, R. B. Patel, U. R. Patel, W. R. Gillespie, W. A. Craig, and K. S. Albert. J. Pharm. Sci. 71:1259–1263 (1982).
H. P. Ringhand, W. A. Ritschel, M. C. Meyer, A. B. Straughn, and B. E. Cabana. J. Pharm. Sci. 72:1409–1412 (1983).
V. P. Shah, P. Knight, V. K. Prasad, and B. E. Cabana. J. Pharm. Sci. 71:822–824 (1982).
N. Aoyagi, H. Ogata, N. Kaniwa, M. Koibuchi, T. Shibazaki, A. Ejima, Y. Katougi, and Y. Omi. J. Pharm. Sci. 71:1167–1172 (1982).
V. K. Prasad, R. S. Rapaka, P. W. Knight, and B. E. Cabana. Int. J. Pharm. 11:81–90 (1982).
D. E. Smith, E. T. Lin, and L. Z. Benet. Drug Metab. Dispos. 8:337–342 (1980).
M. Gibaldi and D. Perrier. In Pharmacokinetics, Marcel Dekker, New York, 1982, pp. 409–416.
K. Yamaoka, T. Nakagawa, and T. Uno. J. Pharmacokin. Biopharm. 6:547–558 (1978).
Y. Tanigawari, K. Yamaoka, T. Nakagawa, and T. Uno. J. Pharm. Sci. 71:1129–1131 (1982).
Y. Tanigawari, K. Yamaoka, T. Nakagawa, and T. Uno. Chem. Pharm. Bull. 30:1088–1090 (1982).
B. Cabana. J. Pharm. Sci. 72:98–99 (1983).
A. Grahnen, M. Hammarland, and T. Lundquist. Eur. J. Pharmacol. 27:595–602 (1984).
J. D. Hayes. J. Pharm. Sci. 70:673 (1981).
J. D. Hayes. J. Pharm. Sci. 72:99–100 (1983).
M. Kingsford, N. J. Eggers, G. Soteros, T. J. B. Maling, and R. J. Shirkey. J. Pharm. Pharmacol. 36:536–538 (1984).
M. L. Crismon, E. S. Waller, R. V. Smith, M. T. Bauza and J. T. Doluisio. Academy of Pharmaceutical Sciences, Montreal, 1984, Abstr. 25.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McNamara, P.J., Foster, T.S., Digenis, G.A. et al. Influence of Tablet Dissolution on Furosemide Bioavailability: A Bioequivalence Study. Pharm Res 4, 150–153 (1987). https://doi.org/10.1023/A:1016427321532
Issue Date:
DOI: https://doi.org/10.1023/A:1016427321532